HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $16.80 Consensus Price Target from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been given a consensus rating of “Hold” by the five ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.80.

A number of research analysts have recently commented on HCM shares. Wall Street Zen downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings cut HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. Bank of America decreased their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, March 10th. Finally, Morgan Stanley set a $13.60 target price on HUTCHMED in a report on Thursday, May 28th.

HUTCHMED Stock Performance

NASDAQ HCM opened at $10.49 on Wednesday. HUTCHMED has a 12 month low of $10.40 and a 12 month high of $19.50. The company has a 50-day moving average of $12.92 and a 200-day moving average of $13.88. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05.

Institutional Trading of HUTCHMED

A number of institutional investors have recently modified their holdings of the company. State Street Corp grew its holdings in shares of HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares during the period. M&G PLC grew its holdings in shares of HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after purchasing an additional 54,601 shares during the period. Amundi grew its holdings in shares of HUTCHMED by 4.0% during the 1st quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after purchasing an additional 8,916 shares during the period. Jane Street Group LLC grew its holdings in shares of HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after purchasing an additional 124,771 shares during the period. Finally, UBS Group AG boosted its holdings in HUTCHMED by 112.8% in the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the period. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.